Table 4.
Combination therapies involving PD-L1 antibody (Atezolizumab) and the regulatory inhibitors in 2017.
| NCT number | Recruitment | Conditions | Other interventions | Phase |
|---|---|---|---|---|
| NCT03434379 | Recruiting | Carcinoma, hepatocellular | Bevacizumab, Sorafenib | III |
| NCT03395899 | Recruiting | Breast cancer Estrogen receptor-positive breast cancer | Cobimetinib, Ipatasertib, Bevacizumab | II |
| NCT03363867 | Not yet recruiting | Ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma | Bevacizumab, Cobimetinib | II |
| NCT03340558 | Not yet recruiting | Metastatic colorectal cancer | Cobimetinib | II |
| NCT03337698 | Recruiting | Carcinoma, NSCLC | Cobimetinib, RO6958688, Docetaxel, BL-8040, Tazemetostat, CPI-444, Pemetrexed, Carboplatin, Gemcitabine | I/II |
| NCT03312630 | Recruiting | Multiple myeloma | Cobimetinib, Venetoclax | I/II |
| NCT03292172 | Recruiting | Advanced ovarian cancer, triple negative breast cancer | RO6870810 | I |
| NCT03280563 | Recruiting | Breast neoplasms | Bevacizumab, Cobimetinib, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen | I/II |
| NCT03273153 | Recruiting | Advanced BRAFV600 wild-type melanoma | Cobimetinib, Pembrolizumab | III |
| NCT03264066 | Recruiting | Solid Tumors | Cobimetinib | II |
| NCT03202316 | Recruiting | Malignant neoplasm of breast | Cobimetinib, Eribulin | II |
| NCT03201458 | Recruiting | Non-resectable cholangiocarcinoma | Cobimetinib, Laboratory biomarker analysis | II |
| NCT03178851 | Recruiting | Malignant melanoma | Cobimetinib | I |
| NCT03170960 | Recruiting | Urothelial carcinoma, renal cell carcinoma | Cabozantinib | I/II |
| NCT02314481 | Recruiting | Malignant neoplasms of digestive organs, melanoma, other malignant neoplasms of skin, appendiceal adenocarcinoma, cutaneous squamous cell carcinoma, small bowel adenocarcinoma | Cobimetinib | II |
| NCT02314481 | Recruiting | NSCLC | Vemurafenib, Alectinib, Trastuzumab emtansine | II |